HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco

Autoři: Kimberly Page aff001;  Jennifer L. Evans aff002;  Judith A. Hahn aff002;  Peter Vickerman aff004;  Stephen Shiboski aff002;  Meghan D. Morris aff002
Působiště autorů: Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America aff001;  Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States of America aff002;  Department of Medicine, University of California San Francisco, San Francisco, CA, United States of America aff003;  Population Health Sciences, University of Bristol, Bristol, United Kingdom aff004
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: 10.1371/journal.pone.0226166



HCV incidence is increasing in the US, notably among younger people who inject drugs (PWID). In a cohort of young adult (age<30 years) PWID in San Francisco we examined whether ‘injecting partner mixing’ factors, i.e. age of partner and knowledge of their HCV serostatus, were associated with HCV transmission.


In 448 susceptible PWID studied prospectively. All participants were asked to report characteristics and behaviors they engaged in with up to 3 injecting partners defined as “people whom you injected the most with” in the past month”. These partnerships did not specify that drugs or injecting equipment was shared. HCV incidence was estimated by age of up to 3 injecting partners, categorized as: (i) all <30; (ii) mixed-age (<&≥30); and (iii) all ≥30 years and perceived knowledge of the HCV status of participants’ injecting partners’ HCV status. Interaction was evaluated between partnership age categories and perceived HCV status of partners.


Between 2006–2018, overall HCV incidence (/100 person years observation [pyo]) was 19.4 (95% CI: 16.4, 22.9). Incidence was highest in those with mixed-age partnerships: 28.5 (95% CI: 21.8, 37.1) and those whose partners were all <30 (23.9; 95% CI: 18.8, 30.4), and lowest if partners were ≥30 (7.5; 95% CI: 4.8, 11.8). In a multivariable analyses adjusting for age, sex (of index), injection frequency, and injection partnership ‘monogamy’, we found evidence for an interaction: the highest HCV incidence was seen in PWID whose partners were all <30 and who knew at least one of their partners was HCV-positive (58.9, 95% CI: 43.3, 80.0; p<0.01).


Younger injectors are more likely to acquire HCV from their similarly-aged peers, than older injecting partners. Protective seroadaptive behavior may contribute to reduce incidence. These findings can inform new HCV prevention approaches for young PWID needed to curb the HCV epidemic.

Klíčová slova:

Antibodies – Behavior – Equipment – Hepatitis C virus – Heroin – Interpersonal relationships – Young adults


1. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168(10):1099–109. doi: 10.1093/aje/kwn237 18849303

2. Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis. 2012;55 Suppl 1:S3–9.

3. Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis. 2014;59(10):1411–9. doi: 10.1093/cid/ciu643 25114031

4. Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, et al. Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014. Am J Public Health. 2017:e1–e7.

5. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002;186(11):1558–64. doi: 10.1086/345554 12447730

6. Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009;200(8):1216–26. doi: 10.1086/605947 19764883

7. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising Mortality Associated With Hepatitis C Virus in the United States, 2003–2013. Clin Infect Dis. 2016;62(10):1287–8. doi: 10.1093/cid/ciw111 26936668

8. McFarlane T. Emergence of acute hepatitis C in young Indiana residents who inject drugs. https://wwwingov/isdh/files/HCV_Cluster_Investigation_-Finalpdf. 2011.

9. Conrad C, Bradley HM, Broz D, Buddha S, Chapman EL, Galang RR, et al. Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone—Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443–4. 25928470

10. Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged </ = 30 years—Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb Mortal Wkly Rep. 2015;64(17):453–8. 25950251

11. Evans ME, Labuda SM, Hogan V, Agnew-Brune C, Armstrong J, Periasamy Karuppiah AB, et al. Notes from the Field: HIV Infection Investigation in a Rural Area—West Virginia, 2017. MMWR Morb Mortal Wkly Rep. 2018;67(8):257–8. doi: 10.15585/mmwr.mm6708a6 29494569

12. Centers for Disease C, Prevention. Notes from the field: risk factors for hepatitis C virus infections among young adults—Massachusetts, 2010. MMWR Morb Mortal Wkly Rep. 2011;60(42):1457–8. 22031220

13. Freyer F. HIV outbreak in Lawrence, Lowell is bigger than officials thought. Boston Globe July 25, 2018 https://wwwbostonglobecom/metro/2018/07/25/hiv-outbreak-lawrence-lowell-bigger-than-officials-thought/szlLL75UDcNTPeB022NptI/storyhtml Accessed July 26, 2018. 2018.

14. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155(7):645–53. doi: 10.1093/aje/155.7.645 11914192

15. Hagan H, Pouget ER, Williams IT, Garfein RL, Strathdee SA, Hudson SM, et al. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J Infect Dis. 2010;201(3):378–85. doi: 10.1086/649783 20053137

16. Esmaeili A, Mirzazadeh A, Morris MD, Hajarizadeh B, Sacks HS, Maher L, et al. The effect of female sex on hepatitis C incidence among people who inject drugs: results from the international multi-cohort InC3 Collaborative. Clin Infect Dis. 2017.

17. Boodram B, Hotton AL, Shekhtman L, Gutfraind A, Dahari H. High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members. J Urban Health. 2017.

18. Bourgois P, Prince B, Moss A. The everyday violence of Hepatitis C among young women who inject drugs in San Francisco. Human Organization. 2004(63):253–64.

19. Tseng FC, T R O'Brien, M Zhang, AH Kral, BA Ortiz-Conde, J Lorvick, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology. 2007.

20. Abara WE, Trujillo L, Broz D, Finlayson T, Teshale E, Paz-Bailey G, et al. Age-related Differences in Past or Present HCV Infection among People Who Inject Drugs—National HIV Behavioral Surveillance, Eight U.S Cities, 2015. J Infect Dis. 2019.

21. Eckhardt B, Winkelstein ER, Shu MA, Carden MR, McKnight C, Des Jarlais DC, et al. Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention. PLoS One. 2017;12(5):e0177341. doi: 10.1371/journal.pone.0177341 28542351

22. Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;9:CD012021. doi: 10.1002/14651858.CD012021.pub2 28922449

23. Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174(12):1974–81. doi: 10.1001/jamainternmed.2014.5416 25347412

24. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis. 2013;57 Suppl 2:S32–8.

25. Hahn JA, Evans JL, Davidson PJ, Lum PJ, Page K. Hepatitis C virus risk behaviors within the partnerships of young injecting drug users. Addiction. 2010;105(7):1254–64. doi: 10.1111/j.1360-0443.2010.02949.x 20491725

26. Koester S, Booth RE, Zhang Y. The prevalence of additional injection-related HIV risk behaviors among injection drug users. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1996;12(2):202–7. doi: 10.1097/00042560-199606010-00015 8680893

27. Koester S, Glanz J, Baron A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav. 2005;9(1):27–39. doi: 10.1007/s10461-005-1679-y 15812611

28. Johnson RA, Gerstein DR, Pach A 3rd, Cerbone FG, Brown J. HIV risk behaviors in African-American drug injector networks: implications of injection-partner mixing and partnership characteristics. Addiction. 2002;97(8):1011–24. doi: 10.1046/j.1360-0443.2002.00165.x 12144604

29. Grund JP, Friedman SR, Stern LS, Jose B, Neaigus A, Curtis R, et al. Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. Soc Sci Med. 1996;42(5):691–703. doi: 10.1016/0277-9536(95)00193-x 8685737

30. Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med. 2005;61(5):1026–44. doi: 10.1016/j.socscimed.2004.12.024 15955404

31. El-Bassel N, Shaw SA, Dasgupta A, Strathdee SA. People who inject drugs in intimate relationships: it takes two to combat HIV. Curr HIV/AIDS Rep. 2014;11(1):45–51. doi: 10.1007/s11904-013-0192-6 24477931

32. Morris MD, Evans J, Montgomery M, Yu M, Briceno A, Page K, et al. Intimate injection partnerships are at elevated risk of high-risk injecting: a multi-level longitudinal study of HCV-serodiscordant injection partnerships in San Francisco, CA. PLoS One. 2014;9(10):e109282. doi: 10.1371/journal.pone.0109282 25286346

33. Jain J, Evans JL, Briceno A, Page K, Hahn JA. Comparison of phosphatidylethanol results to self-reported alcohol consumption among young injection drug users. Alcohol. 2014;49(5):520–4.

34. Page-Shafer K, Pappalardo BL, Tobler LH, Phelps BH, Edlin BR, Moss AR, et al. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol. 2008;46(2):499–506. doi: 10.1128/JCM.01229-07 18032621

35. Jacka B, Applegate T, Krajden M, Olmstead A, Harrigan PR, Marshall BD, et al. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. Hepatology. 2014;60(5):1571–80. doi: 10.1002/hep.27310 25042607

36. Jacka B, Applegate T, Poon AF, Raghwani J, Harrigan PR, DeBeck K, et al. Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada. J Hepatol. 2016;64(6):1247–55. doi: 10.1016/j.jhep.2016.02.031 26924451

37. Arthur RF, Gurley ES, Salje H, Bloomfield LS, Jones JH. Contact structure, mobility, environmental impact and behaviour: the importance of social forces to infectious disease dynamics and disease ecology. Philos Trans R Soc Lond B Biol Sci. 2017;372(1719).

38. Edmunds WJ, O'Callaghan CJ, Nokes DJ. Who mixes with whom? A method to determine the contact patterns of adults that may lead to the spread of airborne infections. Proc Biol Sci. 1997;264(1384):949–57. doi: 10.1098/rspb.1997.0131 9263464

39. Del Valle SY, Hyman JM, Hethcote HW, Eubank SG. Mixing pattners between age groups in social networks. Soc Networks. 2007;29:539–54.

40. Kral AH, Lorvick J, Edlin BR. Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. Journal of Acquired Immune Deficiency Syndromes. 2000;24(2):162–7. doi: 10.1097/00126334-200006010-00011 10935692

41. Tsui JI, Vittinghoff E, Hahn JA, Evans JL, Davidson PJ, Page K. Risk behaviors after hepatitis C virus seroconversion in young injection drug users in San Francisco. Drug Alcohol Depend. 2009;105(1–2):160–3. doi: 10.1016/j.drugalcdep.2009.05.022 19647375

42. Collier MG, Bhaurla SK, Cuevas-Mota J, Armenta RF, Teshale EH, Garfein RS. Awareness of HCV infection among persons who inject drugs in San Diego, California. Am J Public Health. 2015;105(2):302–3. doi: 10.2105/AJPH.2014.302245 25521877

43. McFarland W, Chen YH, Raymond HF, Nguyen B, Colfax G, Mehrtens J, et al. HIV seroadaptation among individuals, within sexual dyads, and by sexual episodes, men who have sex with men, San Francisco, 2008. Aids Care. 2011;23(3):261–8. doi: 10.1080/09540121.2010.507748 21347888

44. Morris MD, Andrew E, Tan JY, Maher L, Hoff C, Darbes L, et al. Injecting-related trust, cooperation, intimacy, and power as key factors influencing risk perception among drug injecting partnerships. PLoS One. 2019;14(5):e0217811. doi: 10.1371/journal.pone.0217811 31150518

45. Rhodes T, Davis M, Judd A. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction. 2004;99(5):621–33. doi: 10.1111/j.1360-0443.2004.00692.x 15078237

46. Jones L, Atkinson A, Bates G, McCoy E, Porcellato L, Beynon C, et al. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: systematic review of qualitative research. Int J Drug Policy. 2014;25(2):204–11. doi: 10.1016/j.drugpo.2013.11.004 24332457

47. Roy E, Nonn E, Haley N, Cox J. Hepatitis C meanings and preventive strategies among street-involved young injection drug users in Montreal. Int J Drug Policy. 2007;18(5):397–405. doi: 10.1016/j.drugpo.2007.02.005 17854728

48. Rance J, Rhodes T, Fraser S, Bryant J, Treloar C. Practices of partnership: Negotiated safety among couples who inject drugs. Health (London). 2016. doi: 10.1016/j.jogc.2016.03.005

49. Smith MK, Graham M, Latkin CA, Go VL. Using Contact Patterns to Inform HIV Interventions in Persons Who Inject Drugs in Northern Vietnam. J Acquir Immune Defic Syndr. 2018;78(1):1–8. doi: 10.1097/QAI.0000000000001632 29389769

50. Hahn JA, Tully DC, Evans JL, Morris MD, Briceno A, Bean DJ, et al. Role of HCV Viremia in Corroborated HCV Transmission Events Within Young Adult Injecting Partnerships. Open Forum Infect Dis. 2019;6(4):ofz125. doi: 10.1093/ofid/ofz125 31041340

51. Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, et al. Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study. PLoS One. 2015;10(4):e0122232. doi: 10.1371/journal.pone.0122232 25837807

52. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011;54(6):1137–44. doi: 10.1016/j.jhep.2010.08.029 21145810

53. Hellard M, Rolls DA, Sacks-Davis R, Robins G, Pattison P, Higgs P, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology. 2014;60(6):1861–70. doi: 10.1002/hep.27403 25163856

54. Hahn J, Wylie D, Dill J, Sanchez MS, Lloyd-Smith JO, Page-Shafer K, et al. Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. Epidemics. 2009;1:47–57. doi: 10.1016/j.epidem.2008.10.002 20445816

55. Rowe C, Santos GM, Raymond HF, Coffin PO. Social mixing and correlates of injection frequency among opioid use partnerships. Int J Drug Policy. 2017;41:80–8. doi: 10.1016/j.drugpo.2016.11.016 28113118

56. Coffin PO, Jin H, Huriaux E, Mirzazadeh A, Raymond HF. Trends in use of health care and HIV prevention services for persons who inject drugs in San Francisco: results from National HIV Behavioral Surveillance 2005–2012. Drug Alcohol Depend. 2015;146:45–51. doi: 10.1016/j.drugalcdep.2014.10.025 25468816

57. Schuman-Olivier Z, Weiss RD, Hoeppner BB, Borodovsky J, Albanese MJ. Emerging adult age status predicts poor buprenorphine treatment retention. J Subst Abuse Treat. 2014;47(3):202–12. doi: 10.1016/j.jsat.2014.04.006 24953168

58. Marsch LA, Moore SK, Borodovsky JT, Solhkhah R, Badger GJ, Semino S, et al. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction. 2016;111(8):1406–15. doi: 10.1111/add.13363 26918564

59. Hadland SE, Bagley SM, Rodean J, Silverstein M, Levy S, Larochelle MR, et al. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder. JAMA Pediatr. 2018.

Článek vyšel v časopise


2019 Číslo 12